Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy

References

1. 1.↵
   2. Planchard D,
   3. Feng PH,
   4. Karaseva N,
   5. Kim SW,
   6. Kim TM,
   7. Lee CK, et al.

   Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open. 2021; 6: 100271.
2. 2.↵
   2. Qin BD,
   3. Jiao XD,
   4. Yuan LY,
   5. Wu Y,
   6. Ling Y,
   7. Zang YS.

   Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. J Immunother Cancer. 2024; 12: e008818.
3. 3.↵
   2. Borcoman E,
   3. Kanjanapan Y,
   4. Champiat S,
   5. Kato S,
   6. Servois V,
   7. Kurzrock R, et al.

   Novel patterns of response under immunotherapy. Ann Oncol. 2019; 30: 385–96.

   OpenUrlCrossRefPubMed
4. 4.
   2. Gandara DR,
   3. von Pawel J,
   4. Mazieres J,
   5. Sullivan R,
   6. Helland Å,
   7. Han JY, et al.

   Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study. J Thorac Oncol. 2018; 13: 1906–18.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Gang X,
   3. Yan J,
   4. Li X,
   5. Shi S,
   6. Xu L,
   7. Liu R, et al.

   Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: current evidence and future directions. Cancer Lett. 2024; 604: 217241.
6. 6.↵
   2. Wang Z,
   3. Wei L,
   4. Li J,
   5. Zhou H,
   6. Li S,
   7. Chen D, et al.

   Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2021; 10: 4368–79.

   OpenUrlPubMed
7. 7.↵
   2. Reckamp KL,
   3. Redman MW,
   4. Dragnev KH,
   5. Minichiello K,
   6. Villaruz LC,
   7. Faller B, et al.

   Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. J Clin Oncol. 2022; 40: 2295–306.

   OpenUrlCrossRefPubMed
8. 8.↵
   2. Lin G,
   3. Wang Z,
   4. Chu Q,
   5. Hu Y,
   6. Huang D,
   7. Wang J, et al.

   Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thorac Cancer. 2024; 15: 419–26.

   OpenUrlPubMed
9. 9.↵
   2. Feng Y,
   3. Tao Y,
   4. Chen H,
   5. Zhou Y,
   6. Tang L,
   7. Liu C, et al.

   Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer. 2023; 14: 2536–47.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Saal J,
    3. Eckstein M,
    4. Ritter M,
    5. Brossart P,
    6. Luetkens J,
    7. Ellinger J, et al.

    Dissection of progressive disease patterns for a modified classification for immunotherapy. JAMA Oncol. 2025; 11: 154–61.

    OpenUrlPubMed
11. 11.↵
    2. Al Bakir M,
    3. Reading JL,
    4. Gamble S,
    5. Rosenthal R,
    6. Uddin I,
    7. Rowan A, et al.

    Clonal driver neoantigen loss under EGFR TKI and immune selection pressures. Nature. 2025; 639: 1052–9.

    OpenUrlPubMed
12. 12.↵
    2. Syn NL,
    3. Teng MWL,
    4. Mok TSK,
    5. Soo RA.

    De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017; 18: e731–41.

    OpenUrlCrossRefPubMed
13. 13.↵
    2. Herbst RS,
    3. Garon EB,
    4. Kim DW,
    5. Cho BC,
    6. Perez-Gracia JL,
    7. Han JY, et al.

    Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol. 2020; 38: 1580–90.

    OpenUrlCrossRefPubMed
14. 14.↵
    2. Gettinger SN,
    3. Wurtz A,
    4. Goldberg SB,
    5. Rimm D,
    6. Schalper K,
    7. Kaech S, et al.

    Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer. J Thorac Oncol. 2018; 13: 831–9.

    OpenUrlCrossRefPubMed
15. 15.↵
    2. Kitagawa S,
    3. Hakozaki T,
    4. Kitadai R,
    5. Hosomi Y.

    Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thorac Cancer. 2020; 11: 1927–33.

    OpenUrlPubMed